Open innovation networks between academia and industry: an imperative for breakthrough therapies.
about
Co-authorship network analysis in health research: method and potential useDrug Discovery in Academia- the third way?Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.Innovation in biological microscopy: current status and future directions.The innovative medicines initiative: a European response to the innovation challenge.Public-private partnerships need honest brokering.Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest.The future of the pharmaceutical sciences and graduate education: recommendations from the AACP Graduate Education Special Interest GroupThe Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.Early assessment of medical technologies to inform product development and market access: a review of methods and applications.Collaboration versus outsourcing: the need to think outside the box.Ion channel drug discovery: challenges and future directions.The Innovative Medicines Initiative moves translational immunology forward.Accessing external innovation in drug discovery and development.Medical innovation then and now: perspectives of innovators responsible for transformative drugs.Personalized therapy for breast cancer: a dream or a reality?Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?Role of open chemical data in aiding drug discovery and design.The RA-MAP Consortium: a working model for academia-industry collaboration.Global patent landscape of programmed cell death 1: implications of the rapid expansion.Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology.Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) DatabaseThe Reinvigorating of International Entrepreneurship by Open Innovation Strategy for Iranian Businesses
P2860
Q26747916-D9AA01D9-4C6D-46AC-8D85-0734E9EFFD46Q28749049-4CE8741C-3F12-4691-940F-0F086860CE23Q34094097-A25B4EE7-E589-4B7C-BD9F-D8DF416ACF4AQ34191121-ABD7ED9A-86B3-4B8B-BEEC-3BE87465D546Q34253090-180A24F5-34C0-4279-A6DD-FC58B185ADF2Q34259233-F6D4E44F-1CE1-43E5-9FBF-48ACFEED9432Q36369216-60B9D37C-A72A-47F7-883A-DCE8C3F30685Q36874000-23B885CD-4A74-4CDE-A954-9435CE79B6CCQ37734873-A204A8D2-030E-4C2E-A4EB-9AACAC979C64Q37824591-FCE713DE-2F7D-4829-81F7-A6C5A17D7A8FQ37923478-0711912E-6F0C-4BA2-A936-5B4DFA56858EQ37958064-65058AFF-E708-48AB-9B91-3A309ED29610Q37998135-1F7B4FC5-0539-416A-A316-59444305C7E7Q38093624-CF0203BA-18B8-4884-B052-1343AC8B69C3Q38441141-EF4AA94C-A698-4147-8544-BD660796969FQ39063297-848BC38F-8D43-4A4A-8E72-F135CDC46E9DQ39374969-C495646E-76FC-45F1-8CEB-9268A3B6DD20Q39675893-1B8BF199-A4F8-4FD6-BEE6-6A0FA7543217Q42594717-33764F14-2157-4CD3-A75A-01D2F67DD07AQ47355032-FF2EF905-836C-425A-8234-4F2D0FB8626DQ47824551-5F6D6314-611D-44E3-9679-B5505875F0CBQ50052181-0742B61D-7ABE-4767-8065-8B0CE70BB3BCQ56511193-C025701A-10F0-489F-BD22-CF2A3C488878Q58439655-F9829928-DBEA-4FBC-8734-A8F6D52A1FE1
P2860
Open innovation networks between academia and industry: an imperative for breakthrough therapies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Open innovation networks betwe ...... ve for breakthrough therapies.
@en
Open innovation networks betwe ...... ve for breakthrough therapies.
@nl
type
label
Open innovation networks betwe ...... ve for breakthrough therapies.
@en
Open innovation networks betwe ...... ve for breakthrough therapies.
@nl
prefLabel
Open innovation networks betwe ...... ve for breakthrough therapies.
@en
Open innovation networks betwe ...... ve for breakthrough therapies.
@nl
P2093
P2860
P356
P1433
P1476
Open innovation networks betwe ...... ve for breakthrough therapies.
@en
P2093
Julia L Chang
Neal H Cohen
Salima M Lin
Teri Melese
P2860
P2888
P304
P356
10.1038/NM0509-502
P407
P577
2009-05-01T00:00:00Z